{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-17T04:02:27.997624+00:00","company":{"ticker":"RVPH","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"pagination":{"limit":100,"returned":34,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"A.G.P./Alliance Global Partners","detail":"underwriting","count":1,"first_seen":"2026-03-19T23:59:59+00:00","last_seen":"2026-03-19T23:59:59+00:00","evidence_fact_ids":[28157]},{"display_name":"several healthcare-focused institutional investors, and an investment vehicle managed by a firm affiliated with a member of the Company’s Board of Directors","detail":"equity_purchase","count":1,"first_seen":"2023-11-17T23:59:59+00:00","last_seen":"2023-11-17T23:59:59+00:00","evidence_fact_ids":[92376]}]},"facts":[{"fact_type":"earnings_release","fact_key":"41c2c6e4c2bb8775eed0f75556b6a72e0998272f","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-05-13T20:41:28+00:00","payload":{"eps_text":"$0.46 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of approximately $3.2 million, or $0.46 per share","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-13","result_type":"reported_results","revenue_text":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported first quarter ended March 31, 2026 results: net income net loss of approximately $3.2 million, or $0.46 per share, EPS $0.46 per share.","evidence_excerpt":"Reviva Reports First Quarter 2026 Financial Results","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-016760","anchor_url":"https://secwatch.observer/filing/0001437749-26-016760#claim-41c2c6e4c2bb8775eed0f75556b6a72e0998272f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016760/0001437749-26-016760-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"d9bb6829882ab51dfae4195481a128b1170b1086","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-05-13T12:03:45+00:00","payload":{"company_response":null,"compliance_status":"delisting_pending","cure_deadline":"2026-05-11","deficiency_type":"minimum_bid_price","delisting_effective_date":"2026-05-14","exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-05-12","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"May 12, 2026 indicating that the Panel had determined to delist the Company’s common stock from Nasdaq. The Company’s common stock will be suspended from trading on Nasdaq as of the open of trading on May 14, 2026. Begin","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-016538","anchor_url":"https://secwatch.observer/filing/0001437749-26-016538#claim-d9bb6829882ab51dfae4195481a128b1170b1086","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/0001437749-26-016538-index.htm"},{"fact_type":"earnings_release","fact_key":"3f998c7ab69be7554d1ddab285bff747cdee33c9","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-03-30T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the full year ended December 31, 2025","report_date":"2026-03-30","result_type":"reported_results","revenue_text":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported financial results for the full year ended December 31, 2025.","evidence_excerpt":"Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-010140","anchor_url":"https://secwatch.observer/filing/0001437749-26-010140#claim-3f998c7ab69be7554d1ddab285bff747cdee33c9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/0001437749-26-010140-index.htm"},{"fact_type":"material_agreement","fact_key":"e68ca321d7c3688094aac85581b55a34d923f066","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-03-19T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Placement Agency Agreement","agreement_type":"underwriting","counterparty":"A.G.P./Alliance Global Partners","effective_date":"2026-03-18","item_codes_triggered":["1.01"],"value_text":"7.0% of the aggregate gross proceeds"},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at 7.0% of the aggregate gross proceeds (effective 2026-03-18).","evidence_excerpt":"the Company entered into a placement agency agreement (the “Placement Agency Agreement”), dated March 18, 2026, with A.G.P./Alliance Global Partners (the “Placement Agent”) pursuant to which the Company agreed to pay the Placement Agent a total cash fee equal to 7.0% of the aggregate gross proceeds of the Offering","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-009063","anchor_url":"https://secwatch.observer/filing/0001437749-26-009063#claim-e68ca321d7c3688094aac85581b55a34d923f066","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/0001437749-26-009063-index.htm"},{"fact_type":"material_agreement","fact_key":"ff203614192e6d98dabd687538fae538ee1dee2e","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-03-19T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain institutional investors","effective_date":"2026-03-18","item_codes_triggered":["1.01"],"value_text":"$10.0 million"},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. entered into Purchase Agreement with certain institutional investors valued at $10.0 million (effective 2026-03-18).","evidence_excerpt":"On March 18, 2026, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) entered into agreements, including a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered public offering (the “Offering”), (i) an aggregate of 6,283,334 shares (the “Shares”) of the Company’s common stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-009063","anchor_url":"https://secwatch.observer/filing/0001437749-26-009063#claim-ff203614192e6d98dabd687538fae538ee1dee2e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/0001437749-26-009063-index.htm"},{"fact_type":"governance_change","fact_key":"553b2280ce11b94b1526c9c38b43f8e583fabc75","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-03-05T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-03-09","item_codes_triggered":["5.03"],"summary_text":"Filing of Certificate of Amendment to effect a one-for-twenty reverse stock split"},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC.: Filing of Certificate of Amendment to effect a one-for-twenty reverse stock split (effective 2026-03-09).","evidence_excerpt":"filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-006991","anchor_url":"https://secwatch.observer/filing/0001437749-26-006991#claim-553b2280ce11b94b1526c9c38b43f8e583fabc75","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926006991/0001437749-26-006991-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"9454559ae2cda0ec3b64e57c6e93413683146749","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-01-23T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2026-03-27","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-01-20","notice_type":"hearing_update","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq hearing update notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-001913","anchor_url":"https://secwatch.observer/filing/0001437749-26-001913#claim-9454559ae2cda0ec3b64e57c6e93413683146749","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm"},{"fact_type":"governance_change","fact_key":"6d196f616325b44dacb502d951a8d0cb15c46d93","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2025-12-23T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-12-18","item_codes_triggered":["5.03"],"summary_text":"Stockholders approved an amendment to the Certificate of Incorporation to increase authorized shares of Common Stock from 315,000,000 to 515,000,000, filed and effective December 18, 2025."},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC.: Stockholders approved an amendment to the Certificate of Incorporation to increase authorized shares of Common Stock from 315,000,000 to 515,000,000, filed and effective December 18, 2025 (effective 2025-12-18).","evidence_excerpt":"On December 18, 2025, the Company filed the Increase in Authorized Charter Amendment with the Secretary of State of the State of Delaware and such amendment became effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-038602","anchor_url":"https://secwatch.observer/filing/0001437749-25-038602#claim-6d196f616325b44dacb502d951a8d0cb15c46d93","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925038602/0001437749-25-038602-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"bfce187a3a02f6cd0977c359e13454eef6347029","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2025-10-17T23:59:59+00:00","payload":{"company_response":"The Company intends to continue to actively monitor the closing bid price of its common stock and assess potential actions to regain compliance with the Minimum Bid Price Requirement and may, if appropriate, consider and effectuate available options, including implementing a reverse stock split.","compliance_status":"deficient","cure_deadline":"2025-11-10","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-05-13","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2)","reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"May 13, 2025 (the “Minimum Bid Price Notice”), the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Minimum Bid Price Requirement”). The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days preceding the Minimum Bid Price Notice, the Company is not currently in compliance with Minimum Bid Price Requirement. As previou","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-031278","anchor_url":"https://secwatch.observer/filing/0001437749-25-031278#claim-bfce187a3a02f6cd0977c359e13454eef6347029","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925031278/0001437749-25-031278-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"c86cdd1661867ef39d35d079256084b8b717769d","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2025-10-17T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2025-11-10","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-05-13","notice_type":"noncompliance_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"May 13, 2025 (the “Minimum Bid Price Notice”), the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Minimum Bid Price Requirement”). The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days preceding the Minimum Bid Price Notice, the Company is not currently in compliance with Minimum Bid Price Requirement. As previou","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-031278","anchor_url":"https://secwatch.observer/filing/0001437749-25-031278#claim-c86cdd1661867ef39d35d079256084b8b717769d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925031278/0001437749-25-031278-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"26ace889ad54ebcee5f364ebb85e9938e7f892d6","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2025-10-17T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"regained_compliance","cure_deadline":null,"deficiency_type":"market_value","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-10-14","notice_type":"compliance_regained","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(b)(2)","reported_value":null,"rule_numbers":["5550(b)(2)"],"rules_cited_in_text":true},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq compliance regained notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"October 14, 2025, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) received a letter (the “MVLS Compliance Letter”) from the Listing Qualifications Department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) formally notifying the Company that it has regained compliance with the minimum Market Value of Listed Securities (“MVLS”) requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”) and that the MVLS Requirement matter is now closed. The MVLS Compliance Letter was pursuant to a previous notice received on Augu","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-031278","anchor_url":"https://secwatch.observer/filing/0001437749-25-031278#claim-26ace889ad54ebcee5f364ebb85e9938e7f892d6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925031278/0001437749-25-031278-index.htm"},{"fact_type":"governance_change","fact_key":"4b606be0cad877014184ece275c0820f1c45c89c","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2025-09-26T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2025-09-26","item_codes_triggered":["5.03"],"summary_text":"Reduced quorum requirement for stockholder meetings from majority of voting power to one-third of voting power."},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC.: Reduced quorum requirement for stockholder meetings from majority of voting power to one-third of voting power (effective 2025-09-26).","evidence_excerpt":"The Amendment reduces the quorum at all meetings of the Company’s stockholders for the transaction of business, except as otherwise required by law or by the Company’s Amended and Restated Certificate of Incorporation, as amended, or Bylaws, to one-third (331⁄3%) of the voting power of the stock outstanding and entitled to vote at the meeting, present in person, present by remote communication, if applicable, or represented by proxy.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-029951","anchor_url":"https://secwatch.observer/filing/0001437749-25-029951#claim-4b606be0cad877014184ece275c0820f1c45c89c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925029951/0001437749-25-029951-index.htm"},{"fact_type":"auditor_change","fact_key":"ab40fb55ae2c315d5bb64fb559b99cd3ddad5456","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Baker Tilly US, LLP","disagreement_text":null,"effective_date":"2025-06-03","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. engaged Baker Tilly US, LLP as its auditor.","evidence_excerpt":"the Audit Committee of the Company’s Board of Directors appointed Baker Tilly, as the successor to Moss Adams, as the Company’s new independent registered public accounting firm, also effective June 3, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-019716","anchor_url":"https://secwatch.observer/filing/0001437749-25-019716#claim-ab40fb55ae2c315d5bb64fb559b99cd3ddad5456","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925019716/0001437749-25-019716-index.htm"},{"fact_type":"auditor_change","fact_key":"47b21a8ca507086ccceed34be0d182a387f79c1d","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"resignation","auditor_name":"Moss Adams LLP","disagreement_text":null,"effective_date":"2025-06-03","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Baker Tilly US, LLP"},"claim":"Moss Adams LLP resigned as auditor of REVIVA PHARMACEUTICALS HOLDINGS, INC..","evidence_excerpt":"On June 3, 2025, Reviva Pharmaceutical Holdings Inc., (the \"Company\") was notified that Moss Adams LLP (\"Moss Adams\"), the Company's independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025. The combined audit practices will operate as Baker Tilly US, LLP (“Baker Tilly”). In connection with the notification of the merger, Moss Adams has resigned as the auditors of the Company effective June 3, 2025, and the Audit Committee of the Company’s Board of Directors appointed Baker Tilly, as the successor to Moss Adams, as the Company’s new independent registered public accounting firm, also effective June 3, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-019716","anchor_url":"https://secwatch.observer/filing/0001437749-25-019716#claim-47b21a8ca507086ccceed34be0d182a387f79c1d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925019716/0001437749-25-019716-index.htm"},{"fact_type":"governance_change","fact_key":"545661f027ad62282a9ca70946956b26baa04af0","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2024-12-12T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-12-10","item_codes_triggered":["5.03"],"summary_text":"Increased authorized common stock from 115,000,000 to 315,000,000"},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC.: Increased authorized common stock from 115,000,000 to 315,000,000 (effective 2024-12-10).","evidence_excerpt":"On December 10, 2024, the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware and such amendment became effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-037373","anchor_url":"https://secwatch.observer/filing/0001437749-24-037373#claim-545661f027ad62282a9ca70946956b26baa04af0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924037373/0001437749-24-037373-index.htm"},{"fact_type":"earnings_release","fact_key":"522c62980cd45c6fb257130c0905f37750e997ce","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":"$0.25 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $7.4 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported first quarter ended March 31, 2024 results: net income approximately $7.4 million, EPS $0.25 per share.","evidence_excerpt":"The Company reported a net loss of approximately $7.4 million, or $0.25 per share, for the three months ended March 31, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-016364","anchor_url":"https://secwatch.observer/filing/0001437749-24-016364#claim-522c62980cd45c6fb257130c0905f37750e997ce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924016364/0001437749-24-016364-index.htm"},{"fact_type":"earnings_release","fact_key":"0f3d8f784c4b603b5912dbd8ae0a34ceb9c7c457","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2024-04-15T23:59:59+00:00","payload":{"eps_text":"$1.65 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $39.3 million","period_text":"the full year ended December 31, 2023","report_date":"2024-04-15","result_type":"reported_results","revenue_text":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the full year ended December 31, 2023 results: net income approximately $39.3 million, EPS $1.65 per share.","evidence_excerpt":"For the year ended December 31, 2023, net loss was approximately $39.3 million, or $1.65 per share, compared to approximately $28.3 million, or $1.45 per share, for the year ended December 31, 2022 (as restated).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-011953","anchor_url":"https://secwatch.observer/filing/0001437749-24-011953#claim-0f3d8f784c4b603b5912dbd8ae0a34ceb9c7c457","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924011953/0001437749-24-011953-index.htm"},{"fact_type":"material_agreement","fact_key":"91ac03c4f592ee7b0a27360c32628eb90249bb3e","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-11-17T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"several healthcare-focused institutional investors, and an investment vehicle managed by a firm affiliated with a member of the Company’s Board of Directors","effective_date":"2023-11-15","item_codes_triggered":["1.01"],"value_text":"approximately $27.9 million"},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. entered into Securities Purchase Agreement with several healthcare-focused institutional investors, and an investment vehicle managed by a firm affiliated with a member of the Company’s Board of Directors valued at approximately $27.9 million (effective 2023-11-15).","evidence_excerpt":"On November 15, 2023, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with several healthcare-focused institutional investors, and an investment vehicle managed by a firm affiliated with a member of the Company’s Board of Directors (the “Director Affiliate” and collectively, the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers, in a registered direct offering (the “Offering”) priced at the market under Nasdaq rules, an aggregate of (i) 5,268,294 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) exercisable for an aggregate of up to 585,366 shares of Common Stock, and (iii) warrants (the “Warrants”) exercisable for an aggregate of up to 5,853,660 shares of Common Stock.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-032463","anchor_url":"https://secwatch.observer/filing/0001437749-23-032463#claim-91ac03c4f592ee7b0a27360c32628eb90249bb3e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923032463/0001437749-23-032463-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1dfd94107a7970d45935795dc1a87c096dfa31cd","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-11-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-11-13","outcome":"passed","proposal_text":"Ratification of the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"9,917","votes_against":"11,880","votes_for":"14,574,768","votes_withheld":null}]},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. shareholders approved Ratification of the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 at the 2023-11-13 meeting.","evidence_excerpt":"2. The proposal to ratify the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was approved based upon the following votes: Votes For Votes Against Abstentions Broker Non-Votes 14,574,768 11,880 9,917 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-031981","anchor_url":"https://secwatch.observer/filing/0001437749-23-031981#claim-1dfd94107a7970d45935795dc1a87c096dfa31cd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923031981/0001437749-23-031981-index.htm"},{"fact_type":"shareholder_vote","fact_key":"680cbb04c03e17d3da4f7a30a58ba898e3eb819c","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-11-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-11-13","outcome":"passed","proposal_text":"Election of each of Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel and Les Funtleyder as directors","proposal_type":"director_election","results":[{"broker_non_votes":"5,873,081","subject":"Laxminarayan Bhat","votes_abstain":null,"votes_against":null,"votes_for":"8,713,818","votes_withheld":"9,666"},{"broker_non_votes":"5,873,081","subject":"Parag Saxena","votes_abstain":null,"votes_against":null,"votes_for":"7,991,179","votes_withheld":"732,305"},{"broker_non_votes":"5,873,081","subject":"Richard Margolin","votes_abstain":null,"votes_against":null,"votes_for":"8,713,949","votes_withheld":"9,535"},{"broker_non_votes":"5,873,081","subject":"Purav Patel","votes_abstain":null,"votes_against":null,"votes_for":"8,713,807","votes_withheld":"9,677"},{"broker_non_votes":"5,873,081","subject":"Les Funtleyder","votes_abstain":null,"votes_against":null,"votes_for":"8,713,962","votes_withheld":"9,522"}]},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. shareholders approved Election of each of Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel and Les Funtleyder as directors at the 2023-11-13 meeting.","evidence_excerpt":"1. The election of each of Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel and Les Funtleyder as directors to hold office for a term of one year, until their successor is duly elected and qualified or they are otherwise unable to complete their term. The votes were cast for this matter as follows: Votes Broker Non- Nominees Votes For Withheld Votes Laxminarayan Bhat 8,713,818 9,666 5,873,081 Parag Saxena 7,991,179 732,305 5,873,081 Richard Margolin 8,713,949 9,535 5,873,081 Purav Patel 8,713,807 9,677 5,873,081 Les Funtleyder 8,713,962 9,522 5,873,081","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-031981","anchor_url":"https://secwatch.observer/filing/0001437749-23-031981#claim-680cbb04c03e17d3da4f7a30a58ba898e3eb819c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923031981/0001437749-23-031981-index.htm"},{"fact_type":"earnings_release","fact_key":"017a2cf5e8de798e9c1a878fb1c304bb2854e8d0","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-11-14T23:59:59+00:00","payload":{"eps_text":"($0.44) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $10.5 million","period_text":"third quarter ended September 30, 2023","report_date":"2023-11-14","result_type":"reported_results","revenue_text":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported third quarter ended September 30, 2023 results: net income approximately $10.5 million, EPS ($0.44) per share.","evidence_excerpt":"The Company reported a net loss of approximately $10.5 million, or ($0.44) per share, for the three months ended September 30, 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-23-031971","anchor_url":"https://secwatch.observer/filing/0001437749-23-031971#claim-017a2cf5e8de798e9c1a878fb1c304bb2854e8d0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923031971/0001437749-23-031971-index.htm"},{"fact_type":"auditor_change","fact_key":"9f945f7d510e639f5f7727188529c2de166981d3","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-11-14T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Moss Adams LLP","disagreement_text":null,"effective_date":"2023-11-14","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. engaged Moss Adams LLP as its auditor.","evidence_excerpt":"On November 14, 2023, Moss Adams LLP’s engagement as the Company’s new independent registered public accounting firm commenced and became effective.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-031978","anchor_url":"https://secwatch.observer/filing/0001437749-23-031978#claim-9f945f7d510e639f5f7727188529c2de166981d3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923031978/0001437749-23-031978-index.htm"},{"fact_type":"auditor_change","fact_key":"ced8a25b731a19579a727119d9b671748dc74523","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-11-14T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Armanino LLP","disagreement_text":null,"effective_date":"2023-11-14","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Moss Adams LLP"},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. dismissed Armanino LLP as its auditor.","evidence_excerpt":"In light of Armanino LLP’s determination, the Audit Committee of the Company’s Board of Directors initiated a process to select a new accounting firm to serve as the Company’s independent registered public accountant.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-031978","anchor_url":"https://secwatch.observer/filing/0001437749-23-031978#claim-ced8a25b731a19579a727119d9b671748dc74523","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923031978/0001437749-23-031978-index.htm"},{"fact_type":"auditor_change","fact_key":"8a34009a147a669dc1695053efaeb2c1fa4db651","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-10-04T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Moss Adams LLP","disagreement_text":null,"effective_date":"2023-10-04","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. engaged Moss Adams LLP as its auditor.","evidence_excerpt":"sion (the “SEC”) on July 24, 2023, the Company was informed on July 18, 2023 by Armanino LLP (“Armanino”), the Company’s current independent registered public accounting firm, that Armanino would decline to stand for re-appointment after completion of Armanino’s review procedures on the unaudited financial statements of the Company as of and for the three and nine months ended September 30, 2023. Armanino advised the Company that its decision not to stand for reappointment was due to Armanino’s transition away from providing financial statement audit services to public companies. In light of Armanino’s determination, the Audit Committee of the Company’s Board of Directors initiated a process to select a new accounting firm to serve as the Company’s independent registered public accountant. On October 4, 2023, the Audit Committee of the Company’s Board of Directors appointed Moss Adams LL","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-027674","anchor_url":"https://secwatch.observer/filing/0001437749-23-027674#claim-8a34009a147a669dc1695053efaeb2c1fa4db651","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923027674/0001437749-23-027674-index.htm"},{"fact_type":"auditor_change","fact_key":"bca481478b1d221c68448748d346472257410e49","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-10-04T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Armanino LLP","disagreement_text":null,"effective_date":"2023-07-24","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. dismissed Armanino LLP as its auditor.","evidence_excerpt":"(the “Company”) in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on July 24, 2023, the Company was informed on July 18, 2023 by Armanino LLP (“Armanino”), the Company’s current independent registered public accounting firm, that Armanino would decline to stand for re-appointment after completion of Armanino’s review procedures on the unaudited financial statements of the Company as of and for the three and nine months ended September 30, 2023. Armanino advised the Company that its decision not to stand for reappointment was due to Armanino’s transition away from providing financial statement audit services to public companies. In light of Armanino’s determination, the Audit Committee of the Company’s Board of Directors initiated a process to select a new accounting firm to serve as the Company’s independent registered public accountant.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-027674","anchor_url":"https://secwatch.observer/filing/0001437749-23-027674#claim-bca481478b1d221c68448748d346472257410e49","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923027674/0001437749-23-027674-index.htm"},{"fact_type":"earnings_release","fact_key":"c2773eb068953e70d512edab7b5590fe6d601083","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-08-14T23:59:59+00:00","payload":{"eps_text":"($0.86) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of approximately $19.0 million","period_text":"six months ended June 30, 2023","report_date":"2023-08-14","result_type":"reported_results","revenue_text":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported six months ended June 30, 2023 results: net income net loss of approximately $19.0 million, EPS ($0.86) per share.","evidence_excerpt":"The Company reported a net loss of approximately $19.0 million, or ($0.86) per share, for the six months ended June 30, 2023, compared to a net loss of approximately $12.7 million, or ($0.69) per share, for the same period in 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-023680","anchor_url":"https://secwatch.observer/filing/0001437749-23-023680#claim-c2773eb068953e70d512edab7b5590fe6d601083","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923023680/0001437749-23-023680-index.htm"},{"fact_type":"earnings_release","fact_key":"ff04b2c6e203dd095a8db7db41414705aaf3183c","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-08-14T23:59:59+00:00","payload":{"eps_text":"($0.55) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of approximately $12.4 million","period_text":"second quarter ended June 30, 2023","report_date":"2023-08-14","result_type":"reported_results","revenue_text":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported second quarter ended June 30, 2023 results: net income net loss of approximately $12.4 million, EPS ($0.55) per share.","evidence_excerpt":"The Company reported a net loss of approximately $12.4 million, or ($0.55) per share, for the three months ended June 30, 2023, compared to a net loss of approximately $5.3 million, or ($0.29) per share, for the same period in 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-023680","anchor_url":"https://secwatch.observer/filing/0001437749-23-023680#claim-ff04b2c6e203dd095a8db7db41414705aaf3183c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923023680/0001437749-23-023680-index.htm"},{"fact_type":"earnings_release","fact_key":"c9af13ca866221f15b184dd0e63ceb00ddacd2e8","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-05-15T23:59:59+00:00","payload":{"eps_text":"$0.30 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $6.6 million","period_text":"the first quarter ended March 31, 2023","report_date":"2023-05-15","result_type":"reported_results","revenue_text":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the first quarter ended March 31, 2023 results: net income approximately $6.6 million, EPS $0.30 per share.","evidence_excerpt":"The Company reported a net loss of approximately $6.6 million, or $0.30 per share, for the three months ended March 31, 2023, compared to a net loss of approximately $7.4 million, or $0.40 per share, for the same period in 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-014572","anchor_url":"https://secwatch.observer/filing/0001437749-23-014572#claim-c9af13ca866221f15b184dd0e63ceb00ddacd2e8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923014572/0001437749-23-014572-index.htm"},{"fact_type":"earnings_release","fact_key":"2630d61a80d5ed984204bafdbef675da47a899cc","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-03-30T23:59:59+00:00","payload":{"eps_text":"$1.25 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $24.3 million","period_text":"full year ended December 31, 2022","report_date":"2023-03-30","result_type":"reported_results","revenue_text":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported full year ended December 31, 2022 results: net income approximately $24.3 million, EPS $1.25 per share.","evidence_excerpt":"For the year ended December 31, 2022, net loss was approximately $24.3 million, or $1.25 per share","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-23-008498","anchor_url":"https://secwatch.observer/filing/0001437749-23-008498#claim-2630d61a80d5ed984204bafdbef675da47a899cc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923008498/0001437749-23-008498-index.htm"},{"fact_type":"earnings_release","fact_key":"84f4add3a4004c6ed7346fb1072d351e29f5398b","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2022-11-14T23:59:59+00:00","payload":{"eps_text":"($0.87) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $16.2 million","period_text":"the nine months ended September 30, 2022","report_date":"2022-11-14","result_type":"reported_results","revenue_text":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the nine months ended September 30, 2022 results: net income approximately $16.2 million, EPS ($0.87) per share.","evidence_excerpt":"The Company reported a net loss of approximately $16.2 million, or ($0.87) per share, for the nine months ended September 30, 2022, compared to a net loss of approximately $4.8 million, or ($0.36) per share, for the same period in 2021.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-22-027263","anchor_url":"https://secwatch.observer/filing/0001437749-22-027263#claim-84f4add3a4004c6ed7346fb1072d351e29f5398b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774922027263/0001437749-22-027263-index.htm"},{"fact_type":"earnings_release","fact_key":"c219c95721f80de9fe3c680837126fd973f170e4","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2022-11-14T23:59:59+00:00","payload":{"eps_text":"($0.18) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $3.5 million","period_text":"the three months ended September 30, 2022","report_date":"2022-11-14","result_type":"reported_results","revenue_text":null},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the three months ended September 30, 2022 results: net income approximately $3.5 million, EPS ($0.18) per share.","evidence_excerpt":"The Company reported a net loss of approximately $3.5 million, or ($0.18) per share, for the three months ended September 30, 2022, compared to a net loss of approximately $2.3 million, or ($0.12) per share, for the same period in 2021.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-22-027263","anchor_url":"https://secwatch.observer/filing/0001437749-22-027263#claim-c219c95721f80de9fe3c680837126fd973f170e4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774922027263/0001437749-22-027263-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3ef6f8a1dd865b0d795e95689be1877eafcd8ae3","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2022-11-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-11-10","outcome":"passed","proposal_text":"Ratification of the appointment of Armanino LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"21,489","votes_against":"11,054","votes_for":"12,986,442","votes_withheld":null}]},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. shareholders approved Ratification of the appointment of Armanino LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022 at the 2022-11-10 meeting.","evidence_excerpt":"2. The proposal to ratify the appointment of Armanino LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2022 was approved based upon the following votes: Votes For Votes Against Abstentions Broker Non-Votes 12,986,442 11,054 21,489 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-22-027079","anchor_url":"https://secwatch.observer/filing/0001437749-22-027079#claim-3ef6f8a1dd865b0d795e95689be1877eafcd8ae3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774922027079/0001437749-22-027079-index.htm"},{"fact_type":"shareholder_vote","fact_key":"05c3b557d1bddd5a3e80bb7374a59171e9780fd1","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2022-11-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-11-10","outcome":"passed","proposal_text":"Election of each of Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel and Les Funtleyder as directors","proposal_type":"director_election","results":[{"broker_non_votes":"4,702,220","subject":"Laxminarayan Bhat","votes_abstain":null,"votes_against":null,"votes_for":"8,305,931","votes_withheld":"10,834"},{"broker_non_votes":"4,702,220","subject":"Parag Saxena","votes_abstain":null,"votes_against":null,"votes_for":"7,787,682","votes_withheld":"529,083"},{"broker_non_votes":"4,702,220","subject":"Richard Margolin","votes_abstain":null,"votes_against":null,"votes_for":"8,306,224","votes_withheld":"10,541"},{"broker_non_votes":"4,702,220","subject":"Purav Patel","votes_abstain":null,"votes_against":null,"votes_for":"8,296,697","votes_withheld":"20,068"},{"broker_non_votes":"4,702,220","subject":"Les Funtleyder","votes_abstain":null,"votes_against":null,"votes_for":"8,306,214","votes_withheld":"10,551"}]},"claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. shareholders approved Election of each of Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel and Les Funtleyder as directors at the 2022-11-10 meeting.","evidence_excerpt":"1. The election of each of Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel and Les Funtleyder as directors to hold office for a term of one year, until their successor is duly elected and qualified or they are otherwise unable to complete their term. The votes were cast for this matter as follows: Votes Broker Non- Nominees Votes For Withheld Votes Laxminarayan Bhat 8,305,931 10,834 4,702,220 Parag Saxena 7,787,682 529,083 4,702,220 Richard Margolin 8,306,224 10,541 4,702,220 Purav Patel 8,296,697 20,068 4,702,220 Les Funtleyder 8,306,214 10,551 4,702,220","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-22-027079","anchor_url":"https://secwatch.observer/filing/0001437749-22-027079#claim-05c3b557d1bddd5a3e80bb7374a59171e9780fd1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774922027079/0001437749-22-027079-index.htm"},{"fact_type":"executive_change","fact_key":"ee6d45fc32","cik":1742927,"ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2022-06-27T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-07-05","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Marc Cantillon resigned as Chief Medical Officer at REVIVA PHARMACEUTICALS HOLDINGS, INC..","evidence_excerpt":"On June 23, 2022, Marc Cantillon, the Chief Medical Officer of Reviva Pharmaceuticals Holdings, Inc. (the “Company”), notified the Company that he will resign as Chief Medical Officer of the Company effective as of July 5, 2022 to pursue additional opportunities.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-22-015928","anchor_url":"https://secwatch.observer/filing/0001437749-22-015928#claim-ee6d45fc32","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774922015928/0001437749-22-015928-index.htm"}]}